Tumour acquisition method and molecular profiling success in advanced cholangiocarcinoma

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45. DOI: https://doi.org/10.3322/caac.21871

Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40. DOI: https://doi.org/10.1016/j.annonc.2022.10.506

Vogel A, Ducreux M. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10(1):104003. DOI: https://doi.org/10.1016/j.esmoop.2024.104003

Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. DOI: https://doi.org/10.1056/EVIDoa2200015

Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–65. DOI: https://doi.org/10.1016/S0140-6736(23)00727-4

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. DOI: https://doi.org/10.1056/NEJMoa0908721

Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen HJ, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109–21. DOI: https://doi.org/10.1016/j.jhep.2021.12.010

Ros-Buxó M, Mauro E, Sauri T, Iserte G, Fuster-Anglada C, Díaz A, et al. Integrating molecular insights into biliary tract cancer management: a review of personalized therapeutic strategies. Curr Oncol. 2024;31:3615–29. DOI: https://doi.org/10.3390/curroncol31070266

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–61. DOI: https://doi.org/10.1158/1078-0432.CCR-18-0078

Kendre G, Murugesan K, Brummer T, Segatto O, Saborowski A, Vogel A. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma. J Hepatol. 2023;78(3):614–26. DOI: https://doi.org/10.1016/j.jhep.2022.11.030

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. DOI: https://doi.org/10.1016/S1470-2045(20)30157-1

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84. DOI: https://doi.org/10.1016/S1470-2045(20)30109-1

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2 -rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39. DOI: https://doi.org/10.1056/NEJMoa2206834

Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, González-Barrallo I, et al. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Br J Cancer. 2021;125(9):1261–9. DOI: https://doi.org/10.1038/s41416-021-01502-x

Lamarca A, Kapacee Z, Breeze M, Bell C, Belcher D, Staiger H, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9(9):2854. DOI: https://doi.org/10.3390/jcm9092854

Ozono Y, Kawakami H, Uchiyama N, Hatada H, Ogawa S. Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers. J Gastroenterol. 2023;58(11):1081–93. DOI: https://doi.org/10.1007/s00535-023-02037-z

Cappello F, Angerilli V, Munari G, Ceccon C, Sabbadin M, Pagni F, et al. FFPE-based NGS approaches into clinical practice: the limits of glory from a pathologist viewpoint. J Pers Med. 2022;12(5):750. DOI: https://doi.org/10.3390/jpm12050750

Peirce V, Paskow M, Qin L, Dadzie R, Rapoport M, Prince S, et al. A systematised literature review of real-world treatment patterns and outcomes in unresectable advanced or metastatic biliary tract cancer. Target Oncol. 2023;18(6):837–52. DOI: https://doi.org/10.1007/s11523-023-01000-5

Olthof PB, Franssen S, van Keulen AM, van der Geest LG, Hoogwater FJH, Coenraad M, et al. Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma. HPB. 2023;25(11):1329–36. DOI: https://doi.org/10.1016/j.hpb.2023.06.019

Malka D, Borbath I, Lopes A, Couch D, Jimenez M, Vandamme T, et al. Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10 – Precision Medicine). ESMO Open. 2025;10(5):104540. DOI: https://doi.org/10.1016/j.esmoop.2025.104540